Alexander Okuliar spoke to The Deal regarding antitrust challenges facing UnitedHealth’s acquisition of Amedisys, including the antitrust division’s comprehensive review of UnitedHealth’s business practices that could provide the agency with additional fodder for a merger challenge.
“It’s ultimately a bad sign for the proposed Amedisys deal because it expands the scope of any [merger] investigation that’s ongoing,” said Alex. “Staff is going to be more attuned to further activity” by UnitedHealth, he emphasized, “and they’re going to be much more experienced and have a better understanding of the industry.”